Literature DB >> 24436526

Lung cancer screening.

Antonio Gutierrez1, Robert Suh1, Fereidoun Abtin1, Scott Genshaft1, Kathleen Brown1.   

Abstract

Lung cancer is the leading cause of cancer death. Although smoking prevention and cessation programs have decreased lung cancer mortality, there remains a large at-risk population. Dismal long-term survival rates persist despite improvements in diagnosis, staging, and treatment. Early efforts to identify an effective screening test have been unsuccessful. Recent advances in multidetector computed tomography have allowed screening studies using low-dose computed tomography (LDCT) to be performed. This set the stage for the National Lung Screening Trial that found that annual LDCT screening benefits individuals at high risk for lung cancer. An understanding of the harmful effects of lung cancer screening is required to help maximize the benefits and decrease the risks of a lung cancer screening program. Although many questions remain regarding LDCT screening, a comprehensive lung cancer screening program of high-risk individuals will increase detection of preclinical and potentially curable disease, creating a new model of lung cancer surveillance and management.

Entities:  

Keywords:  chest radiography; clinical trials; low dose computed tomography; lung cancer; lung cancer screening program; pulmonary nodules; screening

Year:  2013        PMID: 24436526      PMCID: PMC3709936          DOI: 10.1055/s-0033-1342951

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  49 in total

1.  Estimated radiation dose associated with low-dose chest CT of average-size participants in the National Lung Screening Trial.

Authors:  Frederick J Larke; Randell L Kruger; Christopher H Cagnon; Michael J Flynn; Michael M McNitt-Gray; Xizeng Wu; Phillip F Judy; Dianna D Cody
Journal:  AJR Am J Roentgenol       Date:  2011-11       Impact factor: 3.959

Review 2.  Lung cancer.

Authors:  Roy S Herbst; John V Heymach; Scott M Lippman
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

3.  Cancer information sources used by patients to inform and influence treatment decisions.

Authors:  Matthew C Walsh; Amy Trentham-Dietz; Tracy A Schroepfer; Douglas J Reding; Bruce Campbell; Mary L Foote; Stephanie Kaufman; Morgan Barrett; Patrick L Remington; James F Cleary
Journal:  J Health Commun       Date:  2010-06

4.  Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers.

Authors:  Stefan Diederich; Dag Wormanns; Michael Semik; Michael Thomas; Horst Lenzen; Nikolaus Roos; Walter Heindel
Journal:  Radiology       Date:  2002-03       Impact factor: 11.105

5.  CT findings and progression of small peripheral lung neoplasms having a replacement growth pattern.

Authors:  Shodayu Takashima; Yuichiro Maruyama; Minoru Hasegawa; Takeshi Yamanda; Takayuki Honda; Masumi Kadoya; Shusuke Sone
Journal:  AJR Am J Roentgenol       Date:  2003-03       Impact factor: 3.959

6.  A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers.

Authors:  R P Young; R J Hopkins; B A Hay; M J Epton; G D Mills; P N Black; H D Gardner; R Sullivan; G D Gamble
Journal:  Postgrad Med J       Date:  2009-10       Impact factor: 2.401

7.  Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest.

Authors:  Juan P de Torres; Gorka Bastarrika; Juan P Wisnivesky; Ana B Alcaide; Arantza Campo; Luis M Seijo; Jesús C Pueyo; Alberto Villanueva; María D Lozano; Usua Montes; Luis Montuenga; Javier J Zulueta
Journal:  Chest       Date:  2007-12       Impact factor: 9.410

8.  Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer.

Authors:  David J Brenner
Journal:  Radiology       Date:  2004-05       Impact factor: 11.105

9.  Diagnostic delay in lung cancer: a qualitative study.

Authors:  Angela M Tod; Jacqueline Craven; Peter Allmark
Journal:  J Adv Nurs       Date:  2008-02       Impact factor: 3.187

Review 10.  Screening for lung cancer. A critique of the Mayo Lung Project.

Authors:  R S Fontana; D R Sanderson; L B Woolner; W F Taylor; W E Miller; J R Muhm; P E Bernatz; W S Payne; P C Pairolero; E J Bergstralh
Journal:  Cancer       Date:  1991-02-15       Impact factor: 6.860

View more
  6 in total

1.  Effect of smoking on the genetic makeup of toll-like receptors 2 and 6.

Authors:  Muhammad Kohailan; Mohammad Alanazi; Mahmoud Rouabhia; Abdullah Alamri; Narasimha Reddy Parine; Abdullah Alhadheq; Santhosh Basavarajappa; Abdul Aziz Abdullah Al-Kheraif; Abdelhabib Semlali
Journal:  Onco Targets Ther       Date:  2016-11-21       Impact factor: 4.147

2.  Two SNPs in the promoter region of Toll-like receptor 4 gene are not associated with smoking in Saudi Arabia.

Authors:  Muhammad Kohailan; Mohammad Alanazi; Mahmoud Rouabhia; Abdullah Al Amri; Narasimha Reddy Parine; Abdelhabib Semlali
Journal:  Onco Targets Ther       Date:  2017-02-09       Impact factor: 4.147

3.  The plasma glutamate concentration as a complementary tool to differentiate benign PET-positive lung lesions from lung cancer.

Authors:  K Vanhove; P Giesen; O E Owokotomo; L Mesotten; E Louis; Z Shkedy; M Thomeer; P Adriaensens
Journal:  BMC Cancer       Date:  2018-09-03       Impact factor: 4.430

4.  TSLP and TSLP receptors variants are associated with smoking.

Authors:  Abdelhabib Semlali; Mikhlid Almutairi; Arezki Azzi; Narasimha Reddy Parine; Abdullah AlAmri; Saleh Alsulami; Talal Meshal Alumri; Mohammad Saud Alanazi; Mahmoud Rouabhia
Journal:  Mol Genet Genomic Med       Date:  2019-07-09       Impact factor: 2.183

5.  Development of a Prognostic Nomogram for Patients with Lung Adenocarcinoma in the Stages I, II, and III Based on Immune Scores.

Authors:  Hui Xie; Jian-Fang Zhang; Qing Li
Journal:  Int J Gen Med       Date:  2021-11-23

Review 6.  Opportunities to address lung cancer disparities among African Americans.

Authors:  Steven S Coughlin; Patricia Matthews-Juarez; Paul D Juarez; Courtnee E Melton; Mario King
Journal:  Cancer Med       Date:  2014-09-14       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.